Educational

(Ciba Dianabol) Methandrostenolone Scientific Data

Throughout this article, Maethandrostonolone may be referred to as “Dianabol” which was the trade name through which it was originally marketed and sold prior to 2008.

Dianabol is most commonly referred to as “DBOL”

In 2008 Dianabol became a registered trademark and classified as a dietary supplement. This page is intended to provide educational facts about Dianabol beyond what you may find on other websites.

Prior to 2008, most of the Dianabol in circulation contained the active ingredient “methandrostenolone”.

This drug was marketed under the brand name Dianabol by Ciba until 1983, when it finally pulled the plug on the compound due to mounting pressure from the FDA.

But that’s the name that has been synonymous with the drug.

Some of the other nicknames that it is known by are Anabol, Danabol, Vetanabol and the D-Bomb.


Chemical and Molecular Data

PubChem CID: 6300
Molecular Formula: C20H28O2

Commomn Synonyms:
Methandienone

Metandienone

Molecular Weight:  300.4 g/mol

Methandrostenolone is an organic molecular entity.

URL: http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6810
Chemical Entities of Biological Interest (ChEBI) is a database and ontology of molecular entities focused on ‘small’ chemical compounds, that is part of the Open Biomedical Ontologies effort. The term “molecular entity” refers to any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc., identifiable as a separately distinguishable entity.


Methandrostenolone Common Trade Names

Averbol, Dianabol, Danabol, also known as metandienone (INN) or methandienone, is an orally-effective anabolic steroid originally developed in Germany and released in the US in the early 1960s by Ciba Specialty Chemicals. Methandrostenolone is a controlled substance in the United States and Western Europe, but remains popular among bodybuilders.

Consequently, it can be found on the United States black market. However, methandrostenolone is readily available without a prescription in countries such as Mexico (under the trade name Reforvit-b), and is also being manufactured in Asia and many East European countries.

From Human Metabolome Database (HMDB)
Source: Human Metabolome Database (HMDB)
Record Name: Metandienone
URL: http://www.hmdb.ca/metabolites/HMDB0041925

The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.
A synthetic steroid with anabolic properties that are more pronounced than its androgenic effects. It has little progestational activity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1188)


Methandrostenolone IUPAC and Other Common Names

(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one

Molecular Formula HelpNew Window
C20H28O2

MeSH Entry Terms

Medical Subject Heading (MeSH) names or identifiers matching this PubChem Compound record. The matching between the MeSH and compound records is performed by name matching (i.e., identical common names).


Dianabol – Methandrostenolone Synonyms

Methandienone
Metandienone
METHANDROSTENOLONE
72-63-9
Dianabol
Metanabol
Metandienonum
Methandrolone
Metandienon
Nerobol
Metandrostenolon
Metandrostenolone
Metastenol
Nerobolettes

Protobolin
Anabolin
Andoredan
Danabol
Dianabole
Encephan
Naposim
Stenolon
Stenolone
Abirol
Crein
Dehydromethyltestosterone
Geabol
Anabolicum Medivet
Methylandrostenolone
1-Dehydromethyltestosterone
Methandienonum
Perbolin
Compound 17309
Methandrostenolonum
Ciba 17309-ba
1,2-Dehydro-17-methyltestosterone
Metandienonum [Latin]
Metandienona [Spanish]
UNII-COZ1R7EOCC
A1-Dehydromethyltesterone
Methandrostenolone [USP]
Metandrostenolone [DCIT]
Metandienonum [INN-Latin]
MA (VAN)
Ciba 17309 BA
Metandienona [INN-Spanish]
1-Dehydro-17alpha-methyltestosterone
17alpha-Methyl-1-dehydrotestosterone
Testosterone, 1-dehydro-17-methyl-
NSC-42722
1-Dehydro-17-alpha-methyltestosterone
17-alpha-Methyl-1-dehydrotestosterone
delta’-17-Methyltestosterone
TMV 17
17beta-Hydroxy-17-methylandrosta-1,4-dien-3-one
HSDB 3360
COZ1R7EOCC
delta(1)-17alpha-Methyltestosterone
delta-1,17-alpha-Methyltestosterone
EINECS 200-787-2
NSC 42722
MA
Sterolon
delta(sup 1)-17-alpha-Methyltestosterone
17-beta-Hydroxy-17-alpha-methylandrostra-1,4-dien-3-one
1-Dehydro-17-methyltestosterone
Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17beta)-
Metandienone (INN)
Metandienone [INN]
17alpha-Methyl-17beta-hydroxyandrosta-1,4-dien-3-one
Androsta-1,4-dien-3-one, 17beta-hydroxy-17-methyl-
17-alpha-Methyl-17-beta-hydroxy-1,4-androstadien-3-one
NCGC00159415-02
NCGC00159415-04
1-Dehydro-17-.alpha.-methyltestosterone
DSSTox_CID_3276
DSSTox_RID_76952
DSSTox_GSID_23276
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
17-beta-hydroxy-17-methyl-androsta-1,4-dien-3-one
(17beta)-17-hydroxy-17-methylandrosta-1,4-dien-3-one
.delta.’-17-Methyltestosterone
Metandienona
Androsta-1,4-dien-3-one, 17-beta-hydroxy-17-alpha-methyl-
Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17b)-
Androsta-1,4-diene-3-one, 17-hydroxy-17-methyl-, (17beta)-
1-Dehydro-17.alpha.-methyltestosterone
17.alpha.-Methyl-1-dehydrotestosterone
CAS-72-63-9
.DELTA.1-17.alpha.-Methyltestosterone
(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Androsta-1, 17.beta.-hydroxy-17-methyl-
Androsta-1, 17.beta.-hydroxy-17.alpha.-methyl-
Androsta-1, 17-hydroxy-17-methyl-, (17.beta.)-
17-.beta.-hydroxy-17-methyl-androsta-1,4-dien-3-one
17-.beta.-Hydroxy-17-.alpha.-methylandrostra-1,4-dien-3-one
(1S,11S,14S,15S,2R,10R)-14-hydroxy-2,14,15-trimethyltetracyclo[8.7.0.0<2,7>.0< 11,15>]heptadeca-3,6-dien-5-one
alpha-methyltestosterone
DIANABOL (TN)
ARONIS24421
SCHEMBL140928
AC1L1M80
CHEBI:6810
CHEMBL1418176
DTXSID2023276
XWALNWXLMVGSFR-HLXURNFRSA-N
1-Dehydro-17-methyl-Testosterone
BCP10774
NSC42722
NSC51180
ZINC3875469
Tox21_111647
1, 2-Dehydro-17-methyltestosterone
BBL029917
CM0092
LMST02020013
NSC-51180
SBB080825
STK801870
AKOS005267170
Tox21_111647_1
MCULE-1812806265
17-.alpha.-Methyl-1-dehydrotestosterone
NCGC00159415-03
NCGC00159415-05
17alpha-methyl-Androsta-1,4-dien-3-one
AN-41965
CC-30257
laquo deltaRaquo ‘-17-Methyltestosterone
LS-19343
SC-16233
.delta.-1,17-.alpha.-Methyltestosterone
17-alpha-Methylandrostra-1,4-dien-3-one
ST50411312
laquo deltaRaquo 1-17alpha-Methyltestosterone
17-Hydroxy-17-methylandrosta-1,4-dien-3-one
2023-EP2269610A2
2023-EP2270006A1
2023-EP2270011A1
2023-EP2270014A1
2023-EP2272972A1
2023-EP2272973A1
2023-EP2275412A1
2023-EP2275413A1
2023-EP2277865A1
2023-EP2277872A1
2023-EP2277898A2
2023-EP2280008A2
2023-EP2280010A2
2023-EP2280282A1
2023-EP2281559A1
2023-EP2281563A1
2023-EP2281824A1
2023-EP2284149A1
2023-EP2287156A1
2023-EP2289510A1
2023-EP2289882A1
2023-EP2289886A1
2023-EP2292088A1
2023-EP2292228A1
2023-EP2292630A1
2023-EP2295055A2
2023-EP2295409A1
2023-EP2295411A1
2023-EP2295416A2
2023-EP2295417A1
2023-EP2295434A2
2023-EP2298312A1
2023-EP2298735A1
2023-EP2298748A2
2023-EP2298764A1
2023-EP2298765A1
2023-EP2298767A1
2023-EP2298770A1
2023-EP2298783A1
2023-EP2301533A1
2023-EP2301544A1
2023-EP2301931A1
2023-EP2305642A2
2023-EP2305684A1
2023-EP2305825A1
2023-EP2308875A1
2023-EP2311453A1
2023-EP2311806A2
2023-EP2311807A1
2023-EP2311809A1
2023-EP2311837A1
2023-EP2311842A2
2023-EP2314571A2
2023-EP2314587A1
2023-EP2314590A1
2023-EP2314593A1
2023-EP2316457A1
2023-EP2316458A1
2023-EP2316459A1
2023-EP2316825A1
2023-EP2316826A1
2023-EP2316827A1
2023-EP2316828A1
2023-EP2316832A1
2023-EP2316833A1
2023-EP2316836A1
2023-EP2316974A1
2023-EP2371797A1
2023-EP2371798A1
2023-EP2371800A1
2023-EP2371804A1
2023-EP2380872A1
D00389
AB01332687-02
17-Hydroxy-17-methylandrosta-1,4-dien-3-one #
C-18768
17beta-hydroxy-17-methyl-Androsta-1,4-dien-3-one
laquo deltaRaquo (Sup1)-17alpha-Methyltestosterone
Androsta-1,4-dien-3-one, 17alpha-methyltestosterone
17beta-Hydroxy-17-methylandrosta-1,4-dien-3-one, 98%
17beta-hydroxy-17alpha-methyl-Androsta-1,4-dien-3-one
17beta-Hydroxy-17alpha-methylandrosta-1,4-dien-3-one
17-beta-hydroxy-17-methyl-androsta-1,4-dien-3-one (9CI)
17-Hydroxy-17-methyl-(17beta)-Androsta-1,4-dien-3-one
17-Hydroxy-17-methyl-(17beta)-Androsta-1,4-diene-3-one
Androsta-1,4-dien-3-one, 17.alpha.-hydroxy-17-methyl-
Androsta-1,4-dien-3-one, 17beta-hydroxy-17-methyl- (8CI)
17-Hydroxy-17-methylandrosta-1,4-dien-3-one (ACD/Name 4.0)
Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17-beta)-
Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17.alpha.)-
17beta-Hydroxy-17-methylandrosta-1,4-dien-3-one, >=99.0% (HPLC)
17beta-Hydroxy-17-methylandrosta-1,4-dien-3-one, analytical standard
Androsta-1,4-dien-3-one, 17-hydroxy-17-methyl-, (17-beta)- (9CI)
(9S,10R,13S,14S,17S)-17-hydroxy-10,13,17-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
Methandienone solution, 1.0 mg/mL in 1,2-dimethoxyethane, ampule of 1 mL, certified reference material


Therapeutic Uses of Anabolic Androgenic Steroids

Reference: National Library of Medicine’s Medical Subject Headings online file (MeSH, 1999)

A two compartment, double-blind, randomized, parallel study was performed comparing methandrostenolone with placebo in the treatment of osteoporosis. The duration of the study was 24 mo.

Dependent parameters included total body calcium (TBCa), measured by neutron activation analysis: bone mineral content of the radius (BMC), measured by photon absorptiometry; and total body potassium (TBK), measured by total body counting.

A significant increase in TBK occurred in the treated group, primarily in the first 6 mo; thereafter the TBK remained fairly constant. No significant changes in bone mass occurred, except the 6 mo TBCa measurement increased by 11 grams for the methandrostenolone group and decreased by 6 grams for the placebo group (p = .05).

Other evidence also suggests that anabolic steroids may not produce sustained uncoupling of bone formation and bone resorption in osteoporosis. If methandrostenolone is capable of producing an increment in bone mass in osteoporosis, it was not readily observable with the sensitivity of the techniques employed in this study

PMID:7026971

Aloia JF et al; Metabolism 30 (11): 1076-9 (1981)

from HSDB

VETERINARY: orally, to increase nitrogen retention and increase serum protein values aiding in tissue repair and decrease healing time after surgery, burns, or skin grafts. Also in geriatric states, debilitation, and after chronic infections. As aid in calcium retention in senile, corticosteroid induced, or idiopathic osteoporosis.

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 346

Drug Warnings and Possible Side Effects of Methandrostenolone

Use of anabolic steroids by athletes is not recommended. Objective evidence is conflicting and inconclusive as to whether these medications significantly increase athletic performance by increasing muscle strength.

Weight gains reported by athletes are due in part to fluid retention, which is a potentially hazardous side effect of anabolic steroid therapy.

The risk of other unwanted effects, such as testicular atrophy and suppression of spermatogenesis in males; menstrual disturbances and virilization, such as deepening of voice, development of acne, and unnatural growth of body hair in females; peliosis hepatis or other hepatotoxicity; and hepatic cancer outweigh any possible benefit received from anabolic steroids and make their use in athletes inappropriate.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 140

Hepatocellular carcinoma has been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

Hepatic neoplasms have been associated rarely with long-term, high-dose anabolic steroid therapy. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

FDA Pregnancy Category X. /CONTRAINDICATED IN PREGNANCY. Studies in animals and or humans, or investigational or post-marketing reports, have demonstrated positive evidence of fetal abnormalities or risk which clearly outweighs any possible benefit to the patient./

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

It is not known whether anabolic steroids are distributed into breast milk. Problems in humans have not been documented. Women who take anabolic steroids should not breast feed. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

Anabolic steroids should be used with caution in children and adolescents and only by specialists who are aware of their effects on bone maturation because of possible premature epiphyseal closure, precocious sexual development in males, and virilization in females. The epiphyseal maturation may be accelerated more rapidly than linear growth in children, and the effect may continue for 6 months after the medication has been discontinued. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

Treatment of geriatric male patients with anabolic steroids may cause increased risk of prostatic hyperplasia or prostatic carcinoma. In general, dose selection of an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal , or cardiac function, and of concomitant disease or other drug therapy. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141

Except under special circumstances, /anabolic steroids/ should not be used when the following medical problems exist: breast cancer, disseminated, in females with active hypercalcemia; breast cancer in males severe hepatic function impairment; active or history of hypercalcemia (may be exacerbated or recurrence may result); nephrosis or nephrotic phase of nephritis; prostate cancer (tumor growth may be promoted). /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Virilism (acne or oily skin; enlarging clitoris; hoarseness or deepening of voice; menstrual irregularities; unnatural hair growth or loss) /has been reported/ in females only at an incidence more frequent Note: Enlarging clitoris, hoarseness or deepening of voice, and unnatural hair growth or loss usually are not reversible even after prompt discontinuance of therapy. The concurrent use of estrogens will not prevent virilization in females./Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Virilism (acne; enlarging penis; increased frequency of erections; unnatural hair growth) /has been reported/ in prepubertal males only at an incidence more frequent. /Anabolic Steroids/

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Bladder irritability (frequent urge to urinate); breast soreness; gynecomastia (enlargement of breasts), or priapism (frequent or continuing erections) have been reported in postpubertal males only at an incidence more frequent.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Adverse effects having an incidence less frequent in both females and males Anemia, iron deficiency (loss of appetite; sore tongue); edema (swelling of feet or lower legs; rapid weight gain); gastric irritation (nausea; vomiting); hepatic dysfunction (yellow eyes or skin); leukemia (bone pain), or suppression of clotting factors (unusual bleeding).

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Hypercalcemia (mental depression; nausea; vomiting; unusual tiredness) /has been reported/ in females only at an incidence less frequent.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Unexplained darkening of skin /has been reported/ in prepubertal males only at an incidence less frequent.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Prostatic carcinoma or prostatic hyperplasia (difficult or frequent urination) has been reported in geriatric males only at an incidence less frequent.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

Adverse effects having a rare incidence with prolonged therapy; hepatic necrosis (black, tarry stools; continuing feeling of discomfort; headache; continuing unpleasant breath odor; vomiting of blood); hepatocellular carcinoma (abdominal or stomach pain; unexplained weight loss), or peliosis hepatis (continuing loss of appetite; dark-colored urine; fever; hives; light-colored stools; nausea and vomiting; purple- or red-colored spots on body or inside the mouth or nose; sore throat).

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 142

In 6 bodybuilders taking methandrostenolone (up to 20 mg/day intermittent for a yr or more) plasma testosterone levels were low and lh levels reduced. Abnormal liver function tests seen in 3/6, and 1 had mild diabetes with high serum cholesterol triglycerides and uric acids.

Shephard RJ et al; Br J Sports Med 11(4): 170 (1977)Use of long term androgenic anabolic steroids suggest that they may be possible cause of hepatic angiosarcoma.

Falk H et al; Hepatic Angiosarcoma Associated With Androgenic Anabolic Steroids; Lancet 2(11): 1120 (1979)

Anabolic steroids are not recommended for use during pregnancy, since studies in animals have shown that anabolic steroids cause masculinization of the fetus. Risk-benefit must be carefully considered.

Thomson.Micromedex. Drug Information for the Health Care Professional. 25th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2005., p. 141